Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02130791 · ClinicalTrials.gov registry record · NA
Phenotypic and Genotypic Markers of Performance Vulnerability to Sleep Loss
A NA study of Sleep Restriction Then Total Sleep Deprivation and Total Sleep Deprivation Then Sleep Restriction, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT02130791: Completed NA study of Sleep Restriction Then Total Sleep Deprivation and Total Sleep Deprivation Then Sleep Restriction, sponsored by University of Pennsylvania.
NCT02130791 is a NA study of Sleep Restriction Then Total Sleep Deprivation and Total Sleep Deprivation Then Sleep Restriction that has completed, run by University of Pennsylvania. The registered enrollment target is 170 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02130791, a NA study of Sleep Restriction Then Total Sleep Deprivation and Total Sleep Deprivation Then Sleep Restriction, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
Insufficient sleep is common, affecting 20-40% of adults, and resulting from sleep disorders, medical conditions, work demands, stress/emotional distress, and social/domestic responsibilities. It produces significant social, financial and health-related costs, and it has increasingly become a major public health concern as population studies worldwide have found that reduced sleep duration is associated with increased risks of obesity, morbidity, and mortality. It is well established that sleep loss causes fatigue and sleepiness, as well as errors and accidents that are due to its adverse neurobehavioral effects on alertness, mood, and cognitive functions. However, there are substantial, trait-like differences among people in the extent to which they experience such neurobehavioral deficits when sleep deprived. Common genetic variations involved in sleep-wake, circadian, and cognitive regulation may underlie these large inter-individual differences in neurobehavioral vulnerability to sleep deprivation, though it remains unclear whether different types of sleep deprivation involve the same phenotypic responses and same genotypic contributors. This project will be the first large-scale investigation of markers of differential cognitive vulnerability to both acute total sleep loss and chronic partial sleep loss. It will identify individuals who are at significant risk for fatigue and severe impairments from sleep loss. A total of 110 healthy adults will undergo a 13-day laboratory protocol to thoroughly characterize their cognitive, psychological and physiological responses to two of the most common forms of sleep loss--acute total sleep deprivation (1 night of sleep loss) and chronic partial sleep deprivation (5 nights of sleep limited to 4 hr). The findings from this study will represent a critical first step toward tailoring appropriate follow-up interventions for sleep loss and its symptomatic relief by finding predictors of at-risk individuals who should avoid sle
Primary Outcome
3, 10, or 20 minute simple, high-signal-load reaction time (RT)-based test invented by our group and designed to evaluate the ability to sustain attention and respond in a timely manner to salient signals
Conditions Studied
Interventions
- BEHAVIORAL Sleep
Study Locations (1)
Pennsylvania
- Unit for Experimental Psychiatry, Sleep and Chronobiology Laboratory - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-11 |
| Phase | NA |
What the finished NCT02130791 record still lists
NCT02130791 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Sleep Restriction Then Total Sleep Deprivation appearing as the primary indexed condition, and to 1 intervention - of which Sleep is the first listed.
NCT02130791 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02130791 about?
NCT02130791 is a clinical study titled "Phenotypic and Genotypic Markers of Performance Vulnerability to Sleep Loss". Insufficient sleep is common, affecting 20-40% of adults, and resulting from sleep disorders, medical conditions, work demands, stress/emotional distress, and social/domestic responsibilities. It produces significant social, financial and health-related costs, and it has increasingly become a major ...
What is the current status of trial NCT02130791?
This trial is currently completed. It is a NA study. The enrollment target is 170 participants. The study started on 2010-10. Estimated completion is 2015-11.
What conditions does trial NCT02130791 study?
This clinical trial studies the following conditions: Sleep Restriction Then Total Sleep Deprivation, Total Sleep Deprivation Then Sleep Restriction.
What interventions are being tested in trial NCT02130791?
The interventions under investigation include: Sleep (BEHAVIORAL).
Who is sponsoring clinical trial NCT02130791?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02130791 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02130791's enrollment target sits among peer trials
170 614th of 2000 higher than 1,382 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia